Payoneer Reports Third Quarter 2026 Financial Results

Payoneer reported Q3 2026 revenue of $276.9 million, up 2% year over year, and transaction volume of $25.3 billion, up 13%; B2B volume rose 59% to $5.0 billion. Net income increased 6% to $14.9 million, while adjusted EBITDA declined 4% to $68.3 million and interest income fell 8% to $54.7 million. Shareholders approved the Nuvei transaction on September 14, and the company is pursuing regulatory approvals for a targeted mid-2027 close; it also obtained payment licenses in Canada and Israel.

Analysis

The signal is growth quality, not headline volume: B2B is scaling quickly, but the 12 bp year-over-year decline in take rate and weakness in marketplace revenue imply that incremental volume is not translating proportionally into monetization. That leaves PAYO exposed to a mix of lower-yield growth or competitive pricing; sustained B2B growth only supports multiple expansion if revenue per transaction and contribution economics stabilize. The sequential drop in adjusted EBITDA excluding interest income—from $19.3 million to $13.6 million—also tempers the year-over-year improvement and merits scrutiny against operating-cost growth, particularly R&D and depreciation.

Near term, the market may reward B2B momentum, but the more important 1–3 month test is whether core EBITDA recovers and take rates stop falling. Interest income remains a separate rate sensitivity: lower yields can pressure reported revenue even as customer activity grows, so headline revenue may obscure underlying operating progress. New licenses could improve distribution over time, but do not establish near-term revenue contribution.

The mid-2027 Nuvei close target creates a long event-risk window. Shareholder approval is not regulatory clearance; timing slippage, conditions, or integration distraction could cap standalone upside. The contrarian risk is that investors extrapolate B2B volume before it proves profitable; conversely, persistent ARPU growth and stronger B2B monetization would make the current take-rate concern less important. Merger consideration and conditions are not provided, so a merger-arbitrage valuation is not supportable.

Key Decisions for Investors

• Do not chase PAYO solely on B2B volume acceleration. Treat as a watch/hold pending the next report: look for stabilization in take rate and a rebound in adjusted EBITDA excluding interest income.
• For existing exposure, keep position sizing conservative through the regulatory review period; shareholder approval does not remove deal-break or timing risk. Verify required approvals, transaction conditions, consideration, and termination provisions before considering event-driven exposure.
• Set thesis checks for the next 1–3 months: continued B2B growth alongside improving monetization would support the bull case; further take-rate erosion or another sequential decline in core adjusted EBITDA would falsify it and favor reducing exposure.
• Separate operating performance from rate effects: track revenue excluding interest income and customer-fund yields alongside reported revenue. A reported-revenue slowdown alone is less concerning if core monetization holds; deterioration in both would be a stronger negative signal.